Phase I/II Study of Naxitamab and Sacituzumab Govitecan in Patients With Metastatic TNBC

by | Jun 9, 2025 | Clinical Trials | 0 comments

​ Conditions: Metastatic Triple-Negative Breast Cancer

Interventions: Drug: Sacituzumab govitecan; Drug: Naxitamab

Sponsors: M.D. Anderson Cancer Center; Y-mAbs Therapeutics

Not yet recruiting Conditions: Metastatic Triple-Negative Breast Cancer
Interventions: Drug: Sacituzumab govitecan; Drug: Naxitamab
Sponsors: M.D. Anderson Cancer Center; Y-mAbs Therapeutics
Not yet recruiting 

Submit a Comment

Your email address will not be published. Required fields are marked *